Therefore, NLRP3 inflammasome inhibitors, a new type of anti‐inflammatory drug candidate that is different from the directly blocking IL‐1β, promise to alleviate arthritis symptoms and limit gout flare. This evidence concerns the gene IL1B and arthritic joint disease.